

Pere Domingo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7726017/pere-domingo-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

375 papers	9,495 citations	50 h-index	79 g-index
418 ext. papers	11,130 ext. citations	5.9 avg, IF	5.54 L-index

#	Paper	IF	Citations
375	Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19.. <i>PLoS ONE</i> , 2022 , 17, e0262777	3.7	2
374	Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission.. <i>Scientific Reports</i> , 2022 , 12, 640	4.9	2
373	Neuropsychological deficits in patients with cognitive complaints after COVID-19.. <i>Brain and Behavior</i> , 2022 , e2508	3.4	8
372	Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofab595	1	0
371	Air trapping in COVID-19 patients following hospital discharge: retrospective evaluation with paired inspiratory/expiratory thin-section CT.. <i>European Radiology</i> , 2022 , 1	8	0
370	Adipose tissue aging partially accounts for fat alterations in HIV lipodystrophy.. <i>Adipocyte</i> , 2022 , 11, 1433152	3.52	
369	Post-COVID-19 fatigue: the contribution of cognitive and neuropsychiatric symptoms.. <i>Journal of Neurology</i> , 2022 , 1	5.5	4
368	Pulmonary Infections in People Living with HIV.. <i>Radiologic Clinics of North America</i> , 2022 , 60, 507-520	2.3	0
367	Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial. <i>Trials</i> , 2021 , 22, 808	2.8	4
366	Alpha variant SARS-CoV-2 infection: How it all starts. <i>EBioMedicine</i> , 2021 , 74, 103703	8.8	2
365	Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. <i>Lancet HIV</i> , 2021 , 8, e701-e710	7.8	10
364	Growth Differentiation Factor 15 (GDF-15): A Novel Biomarker Associated with Poorer Respiratory Function in COVID-19. <i>Diagnostics</i> , 2021 , 11,	3.8	2
363	Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). <i>Clinical Infectious Diseases</i> , 2021 , 73, e1991-e1999	11.6	1
362	Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV. <i>PLoS ONE</i> , 2021 , 16, e0249515	3.7	0
361	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. <i>Aids</i> , 2021 , 35, 2025-2033	3.93	0
360	FGF21 serum levels are related to insulin resistance, metabolic changes and obesity in Mexican people living with HIV (PLWH). <i>PLoS ONE</i> , 2021 , 16, e0252144	3.7	4
359	Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2. <i>Medicine (United States)</i> , 2021 , 100, e25923	1.8	1

358	Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2380-2393	5.1	2
357	Risk factors for severe outcomes in people with diabetes hospitalised for COVID-19: a cross-sectional database study. <i>BMJ Open</i> , 2021 , 11, e051237	3	0
356	Not all COVID-19 pandemic waves are alike. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1040.e7-1040.e10	10	16
355	Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. <i>Clinical Immunology</i> , 2021 , 223, 108639	9	11
354	The pharmacological management of cardiovascular disease in people living with HIV (PLWH). <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 743-753	4	
353	Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1127-1141	4	3
352	Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 86, 248-257	3.1	1
351	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 499-518	27.4	154
350	Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review. <i>BMC Public Health</i> , 2021 , 21, 1596	4.1	0
349	Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. <i>Lancet HIV</i> , 2021 , 8, e463-e473	7.8	3
348	Previous Vitamin D Supplementation and Morbidity and Mortality Outcomes in People Hospitalised for COVID19: A Cross-Sectional Study. <i>Frontiers in Public Health</i> , 2021 , 9, 758347	6	1
347	eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort. <i>HIV Research and Clinical Practice</i> , 2021 , 22, 78-85	1.7	
346	Glycoprotein Profile Assessed by H-NMR as a Global Inflammation Marker in Patients with HIV Infection. A Prospective Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
345	HIV and antiretroviral therapy-related fat alterations. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 48	51.1	41
344	Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1955-1960	5.1	2
343	Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV. <i>International Journal of Obesity</i> , 2020 , 44, 1970-1973	5.5	9
342	Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists. <i>European Journal of Rheumatology</i> , 2020 , 7, S107-S109	1.7	7
341	Risk of cardiovascular disease in patients with HIV infection undergoing antiretroviral therapy. <i>Revista Clinica Espanola</i> , 2020 , 220, 149-154	0.7	3

340	Pulmonary Thrombosis or Embolism in a Large Cohort of Hospitalized Patients With Covid-19. <i>Frontiers in Medicine</i> , 2020 , 7, 557	4.9	18
339	Linezolid for therapy of meningitis: a cohort study of 26 patients. <i>Infectious Diseases</i> , 2020 , 52, 808-815	3.1	5
338	High circulating SDF-1 and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients. <i>EBioMedicine</i> , 2020 , 62, 103077	8.8	5
337	The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). <i>EBioMedicine</i> , 2020 , 58, 102887	8.8	78
336	Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3334-3343	5.1	3
335	Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3517-3524	5.1	0
334	Characteristics and outcome of spontaneous bacterial meningitis in patients with diabetes mellitus. <i>BMC Infectious Diseases</i> , 2020 , 20, 292	4	3
333	Drug-drug interactions when treating HIV-related metabolic disorders. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 787-802	5.5	4
332	Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort. <i>HIV Medicine</i> , 2019 , 20, 237-247	2.7	20
331	Does choice of antiretroviral drugs matter for inflammation?. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 389-396	3.8	9
330	Standing on the shoulders of giants: two centuries of struggle against meningococcal disease. <i>Lancet Infectious Diseases</i> , 2019 , 19, e284-e294	25.5	5
329	Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. <i>Nefrologia</i> , 2019 , 39, 497-505	1.5	3
328	Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019 , 37, 151-159	0.1	1
327	Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. <i>HIV Medicine</i> , 2019 , 20, 264-273	2.7	7
326	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥ 50 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , 2019 , 68, 597-606	11.6	18
325	Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019 , 37, 151-159	0.9	4
324	IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status. <i>Scientific Reports</i> , 2019 , 9, 15722	4.9	2
323	Long-term efficacy and safety of nevirapine-containing regimens in virologically suppressed patients: a 17-year follow up. <i>HIV Research and Clinical Practice</i> , 2019 , 20, 151-155	1.7	1

322	Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. <i>Nefrologia</i> , 2019 , 39, 497-505	0.4	
321	Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019 , 37, 373-379	0.9	6
320	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019 , 37, 195-202	0.9	7
319	Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA [®] , Because of a Previous Intolerance to cART. PRO-STR Study. <i>Current HIV Research</i> , 2018 , 16, 425-435	1.3	2
318	Effects of docosahexanoic acid supplementation on inflammatory and subcutaneous adipose tissue gene expression in HIV-infected patients on combination antiretroviral therapy (cART). A sub-study of a randomized, double-blind, placebo-controlled study. <i>Cytokine</i> , 2018 , 105, 73-79	4	12
317	Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2018 , 36, 16-20	0.1	
316	Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy. <i>Atherosclerosis</i> , 2018 , 273, 28-36	3.1	12
315	A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients. <i>Aids</i> , 2018 , 32, 565-573	3.5	14
314	Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia. <i>Aids</i> , 2018 , 32, 1309-1316	3.5	4
313	Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018 , 36, 16-20	0.9	4
312	Effects of docosahexanoic acid on metabolic and fat parameters in HIV-infected patients on cART: A randomized, double-blind, placebo-controlled study. <i>Clinical Nutrition</i> , 2018 , 37, 1340-1347	5.9	4
311	Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018 , 36, 268-276	0.9	5
310	Executive summary of the consensus document on osteoporosis in HIV-infected individuals. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018 , 36, 312-314	0.9	5
309	Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue. <i>Aging Cell</i> , 2018 , 17, e12822	9.9	15
308	Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/Elk1 System. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	8
307	Tolerability of Current Antiretroviral Single-Tablet Regimens. <i>AIDS Reviews</i> , 2018 , 20, 141-149	1.5	6
306	Resolved heart tamponade and controlled exophthalmos, facial pain and diabetes insipidus due to Erdheim-Chester disease. <i>BMJ Case Reports</i> , 2018 , 2018,	0.9	2
305	Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations. <i>Aids</i> , 2018 , 32, 2807-2819	3.5	8

304	Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. <i>Aids</i> , 2018 , 32, 1995-2004	3.5	12
303	Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 79, 481-490	3.1	0
302	Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2018 , 36, 268-276	0.1	
301	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofx258	1	16
300	Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2171-2176	5.1	4
299	Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice. <i>AIDS Research and Human Retroviruses</i> , 2017 , 33, 29-32	1.6	5
298	FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss. <i>Clinical Nutrition</i> , 2017 , 36, 861-868	5.9	81
297	Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy. <i>HIV Clinical Trials</i> , 2017 , 18, 49-53		
296	Characteristics and outcome of spontaneous bacterial meningitis in patients with cancer compared to patients without cancer. <i>Medicine (United States)</i> , 2017 , 96, e6899	1.8	5
295	High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients. <i>Metabolism: Clinical and Experimental</i> , 2017 , 71, 163-170	12.7	10
294	Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines. <i>Immunobiology</i> , 2017 , 222, 989-997	3.4	25
293	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2017 , 35, 88-99	0.1	
292	Neisseria meningitidis and purpura fulminans in a woman with chronic liver disease. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, 459	25.5	1
291	Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. <i>Aids</i> , 2017 , 31, 2503-2514	3.5	45
290	ART regimes and fat: the healing hand wielding the sword. <i>Lancet HIV, the</i> , 2017 , 4, e2-e3	7.8	1
289	Very low level viraemia and risk of virological failure in treated HIV-1-infected patients. <i>HIV Medicine</i> , 2017 , 18, 196-203	2.7	11
288	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017 , 35, 88-99	0.9	6
287	Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA-2014-RIS-EST-15 Trial. <i>Clinical Infectious Diseases</i> , 2017 , 65, 2112-2118	11.6	71

286	Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 844-849	5.1	9
285	Improved adipose tissue function with initiation of protease inhibitor-only ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3212-3221	5.1	3
284	HIV/HCV Coinfection in Spain: Prevalence and Patient Characteristics. <i>Journal of Hepatology</i> , 2016 , 64, S617	13.4	2
283	Infection-related and -unrelated malignancies, HIV and the aging population. <i>HIV Medicine</i> , 2016 , 17, 590-600	2.7	31
282	Atazanavir dose reduction: one size does not fit all. <i>Lancet HIV</i> , 2016 , 3, e334-e335	7.8	1
281	Switching antiretroviral regimes for the treatment of HIV: safety implications. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1349-60	4.1	3
280	Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1346-51	5.1	3
279	Bacterial meningitis: the end of the beginning?. <i>Lancet Infectious Diseases</i> , 2016 , 16, 271-2	25.5	9
278	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw059	1	28
277	Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016 , 34, 516.e1-516.e18	0.9	6
276	Prediction of higher cost of antiretroviral therapy (ART) according to clinical complexity. A validated clinical index. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016 , 34, 149-58	0.9	2
275	Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016 , 34, 361-71	0.9	10
274	Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir. <i>HIV Medicine</i> , 2016 , 17, 340-9	2.7	1
273	Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines. <i>Antiviral Research</i> , 2016 , 132, 59-65	10.8	30
272	Drug therapies for HIV-related metabolic disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1327-38	4	5
271	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1571-1577	11.6	40
270	Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016 , 34, 517-23	0.9	10
269	Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy. <i>HIV Clinical Trials</i> , 2016 , 17, 89-95		0

268	Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3510-3514	5.1	6
267	Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1668-1676	11.6	55
266	Circulating fibroblast growth factor 23 (FGF23) levels are associated with metabolic disturbances and fat distribution but not cardiovascular risk in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1825-32	5.1	7
265	Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2015 , 15, 785-92	25.5	111
264	Expression of human and mouse adenine nucleotide translocase (ANT) isoform genes in adipogenesis. <i>International Journal of Biochemistry and Cell Biology</i> , 2015 , 64, 34-44	5.6	2
263	Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2104-7	5.1	20
262	Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015 , 33, 544-56	0.9	8
261	Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. <i>Aids</i> , 2015 , 29, 1205-15	3.5	37
260	Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 69, 206-15	3.1	12
259	Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease. <i>Aids</i> , 2015 , 29, 1493-504	3.5	8
258	Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial. <i>Clinical Infectious Diseases</i> , 2015 , 60, 811-20	11.6	25
257	Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain. <i>HIV Clinical Trials</i> , 2015 , 16, 57-65		13
256	Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study. <i>HIV Clinical Trials</i> , 2015 , 16, 43-8		4
255	Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1139-45	5.1	19
254	Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1130-8	5.1	16
253	The Molecular Signature of HIV-1-Associated Lipomatosis Reveals Differential Involvement of Brown and Beige/Brite Adipocyte Cell Lineages. <i>PLoS ONE</i> , 2015 , 10, e0136571	3.7	11
252	HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels. <i>PLoS ONE</i> , 2015 , 10, e0144789	3.7	4
251	Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort. <i>PLoS ONE</i> , 2015 , 10, e0145701	3.7	18

250	Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfectd subjects. <i>Antiviral Research</i> , 2014 , 104, 59-61	10.8	6
249	Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 81-101	5.5	6
248	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2014 , 32, 447-58	0.9	10
247	Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS). <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1653-9	5.1	18
246	Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2014 , 14, 590-9	25.5	75
245	Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study. <i>PLoS ONE</i> , 2014 , 9, e89088	3.7	21
244	Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals. <i>PLoS ONE</i> , 2014 , 9, e114142	3.7	18
243	ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19814	5.4	3
242	Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19773	5.4	2
241	An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1749-60	4	6
240	Drug safety profile of integrase strand transfer inhibitors. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 431-451	4.1	16
239	Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3368-71	5.1	35
238	Prevalence of ischemic heart disease and management of coronary risk in daily clinical practice: results from a Mediterranean cohort of HIV-infected patients. <i>BioMed Research International</i> , 2014 , 2014, 823058	3	4
237	Peak bone mass in young HIV-infected patients compared with healthy controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 65, 207-12	3.1	26
236	Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1390-6	5.1	19
235	A 48-week study of fat molecular alterations in HIV naïve patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 66, 457-65	3.1	11
234	Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. <i>AIDS Reviews</i> , 2014 , 16, 199-212	1.5	33
233	Consensus document on the management of renal disease in HIV-infected patients. <i>Nefrologia</i> , 2014 , 34 Suppl 2, 1-81	1.5	2

232	The spectrum of acute bacterial meningitis in elderly patients. <i>BMC Infectious Diseases</i> , 2013 , 13, 108	4	42
231	A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. <i>Diabetologia</i> , 2013 , 56, 2524-37	10.3	75
230	Psychopathology and psychosocial adjustment in patients with HIV-associated lipodystrophy. <i>Brazilian Journal of Infectious Diseases</i> , 2013 , 17, 444-9	2.8	3
229	Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2013 , 13, 927-35	25.5	290
228	Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. <i>Clinical Infectious Diseases</i> , 2013 , 57, 112-21	11.6	45
227	Spontaneous gram-negative bacillary meningitis in adult patients: characteristics and outcome. <i>BMC Infectious Diseases</i> , 2013 , 13, 451	4	34
226	The changing pattern of bacterial meningitis in adult patients at a large tertiary university hospital in Barcelona, Spain (1982-2010). <i>Journal of Infection</i> , 2013 , 66, 147-54	18.9	21
225	Fat tissue measurements by dual-energy x-ray absorptiometry: cross-calibration of 3 different fan-beam instruments. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 212-22	3.5	17
224	Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation. <i>Cytokine</i> , 2013 , 61, 808-15	4	21
223	Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 63, 152-60	3.1	19
222	Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1055-64	4	6
221	Hypertrophied facial fat in an HIV-1-infected patient after autologous transplantation from Buffalo hump retains a partial brown-fat-like molecular signature. <i>Antiviral Therapy</i> , 2013 , 18, 635-9	1.6	1
220	Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naïve subjects aged 50 years or older in Spain: the TRIP study. <i>HIV Clinical Trials</i> , 2013 , 14, 204-15		3
219	Differentially altered molecular signature of visceral adipose tissue in HIV-1-associated lipodystrophy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 64, 142-8	3.1	30
218	96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naïve, HIV-1-infected adults: ASSERT study. <i>Antiviral Therapy</i> , 2013 , 18, 905-13	1.6	52
217	Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40:01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients. <i>PLoS ONE</i> , 2013 , 8, e67035	3.7	6
216	Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study. <i>PLoS ONE</i> , 2013 , 8, e70201	3.7	21
215	Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function. <i>Antiviral Therapy</i> , 2013 , 18, 125-30	1.6	13

214	Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapy. <i>PLoS ONE</i> , 2013 , 8, e57347	3.7	10
213	Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. <i>Journal of Infection</i> , 2012 , 64, 204-11	18.9	8
212	Leptin and adiponectin, but not IL18, are related with insulin resistance in treated HIV-1-infected patients with lipodystrophy. <i>Cytokine</i> , 2012 , 58, 253-60	4	22
211	HIV-1 Tat protein impairs adipogenesis and induces the expression and secretion of proinflammatory cytokines in human SGBS adipocytes. <i>Antiviral Therapy</i> , 2012 , 17, 529-40	1.6	22
210	Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. <i>Antiviral Therapy</i> , 2012 , 17, 577-83	1.6	5
209	Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. <i>Antiviral Therapy</i> , 2012 , 17, 337-46	1.6	20
208	Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. <i>Antiviral Therapy</i> , 2012 , 17, 355-64	1.6	98
207	Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2013-9	5.1	8
206	Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 1453-8	5.1	13
205	Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 2987-93	5.9	18
204	Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection. <i>Expert Opinion on Drug Safety</i> , 2012 , 11, 473-85	4.1	8
203	Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 165-70	1.6	2
202	Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 1462-9	5.1	3
201	Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 3369-75	5.9	21
200	Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2479-86	5.1	21
199	Reduced levels of serum FGF19 and impaired expression of receptors for endocrine FGFs in adipose tissue from HIV-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 61, 527-34	3.1	18
198	Response to combined antiretroviral therapy according to gender and origin in a cohort of naïve HIV-infected patients: GESIDA-5808 study. <i>HIV Clinical Trials</i> , 2012 , 13, 131-41		8
197	Identification of recent HIV-1 infection among newly diagnosed cases in Catalonia, Spain (2006-08). <i>European Journal of Public Health</i> , 2012 , 22, 802-8	2.1	12

196	Adipogenic/lipid, inflammatory, and mitochondrial parameters in subcutaneous adipose tissue of untreated HIV-1-infected long-term nonprogressors: significant alterations despite low viral burden. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 61, 131-7	3.1	18
195	Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. <i>Antiviral Therapy</i> , 2012 , 17, 597	1.6	
194	Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA. <i>Aids</i> , 2012 , 26, 2165-74	3.5	10
193	Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. <i>Aids</i> , 2012 , 26, 2315-26	3.5	92
192	Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. <i>Aids</i> , 2012 , 26, 475-81	3.5	60
191	Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. <i>Antiviral Therapy</i> , 2012 , 17, 1011-20	1.6	39
190	Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients. <i>HIV Clinical Trials</i> , 2012 , 13, 61-9		16
189	Methicillin-resistant <i>Staphylococcus aureus</i> meningitis in adults: a multicenter study of 86 cases. <i>Medicine (United States)</i> , 2012 , 91, 10-17	1.8	19
188	Human papillomavirus infection in HIV-1 infected women in Catalonia (Spain): implications for prevention of cervical cancer. <i>PLoS ONE</i> , 2012 , 7, e47755	3.7	15
187	Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study. <i>Current HIV Research</i> , 2012 , 10, 673-8	1.3	2
186	Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. <i>AIDS Reviews</i> , 2012 , 14, 112-23	1.5	40
185	Clinical utility of maraviroc. <i>Clinical Drug Investigation</i> , 2011 , 31, 527-542	3.2	24
184	Prevalence of transmitted antiretroviral resistance and distribution of HIV-1 subtypes among patients with recent infection in Catalonia (Spain) between 2003 and 2005. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2011 , 29, 482-9	0.9	5
183	Adipose tissue biology and HIV-infection. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2011 , 25, 487-99	6.5	56
182	Thymidine kinase 2 deficiency-induced mitochondrial DNA depletion causes abnormal development of adipose tissues and adipokine levels in mice. <i>PLoS ONE</i> , 2011 , 6, e29691	3.7	15
181	Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. <i>Aids</i> , 2011 , 25, 1683-90	3.5	34
180	Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 58, 253-60	3.1	18
179	Lipodystrophy and insulin resistance in combination antiretroviral treated HIV-1-infected patients: implication of resistin. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 57, 16-23	3.1	19

178	Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96. <i>HIV Clinical Trials</i> , 2011 , 12, 313-22		15
177	Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naïve HIV-1 patients: the ARTEN Trial. <i>Antiviral Therapy</i> , 2011 , 16, 339-48	1.6	69
176	Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. <i>Antiviral Research</i> , 2011 , 91, 112-9	10.8	35
175	Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort. <i>BMC Women's Health</i> , 2011 , 11, 36	2.9	9
174	Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001-2009. <i>AIDS Research and Therapy</i> , 2011 , 8, 22	3	42
173	Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 1365-82	5.5	6
172	No relationship between TNF- α genetic variants and combination antiretroviral therapy-related lipodystrophy syndrome in HIV type 1-infected patients: a case-control study and a meta-analysis. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 143-52	1.6	9
171	Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 713-7	1.6	7
170	Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 1061-5	1.6	11
169	Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis. <i>Clinical Infectious Diseases</i> , 2011 , 52, 662-70	11.6	17
168	Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy. <i>Expert Review of Endocrinology and Metabolism</i> , 2011 , 6, 21-30	4.1	2
167	Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 1428-35	5.9	12
166	Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 358-62	5.1	18
165	HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. <i>Nature Medicine</i> , 2010 , 16, 460-5	50.5	441
164	Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2195-203	5.1	20
163	The future of antiretroviral therapy: challenges and needs. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 827-35	5.1	39
162	Immune reconstitution in severely immunosuppressed antiretroviral-naïve HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. <i>AIDS Research and Human Retroviruses</i> , 2010 , 26, 747-57	1.6	15
161	Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. <i>Clinical Infectious Diseases</i> , 2010 , 50, 1033-40	11.6	25

160	Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naïve, HIV-1-infected adults: 48-week results from the ASSERT study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010 , 55, 49-57	3.1	185
159	Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients. <i>Current HIV Research</i> , 2010 , 8, 467-70	1.3	4
158	Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. <i>Current HIV Research</i> , 2010 , 8, 545-53	1.3	40
157	Characteristics and outcome of HIV infection in gypsies in the Spanish VACH Cohort. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2010 , 28, 266-72	0.9	5
156	Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010 , 1801, 392-9	5	61
155	Polyradiculoneuropathy associated to human herpesvirus 2 in an HIV-1-infected patient (Elsberg syndrome): case report and literature review. <i>Sexually Transmitted Diseases</i> , 2010 , 37, 123-5	2.4	11
154	Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. <i>Aids</i> , 2010 , 24, 2629-37	3.5	40
153	Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. <i>Antiviral Therapy</i> , 2010 , 15, 803-16	1.6	6
152	HIV type-1 transgene expression in mice alters adipose tissue and adipokine levels: towards a rodent model of HIV type-1 lipodystrophy. <i>Antiviral Therapy</i> , 2010 , 15, 1021-8	1.6	9
151	Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. <i>Cancer</i> , 2010 , 116, 5306-15	6.4	104
150	Effect of TNF-alpha genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards. <i>BMC Medical Genetics</i> , 2010 , 11, 63	2.1	18
149	Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome. <i>PLoS ONE</i> , 2010 , 5, e13896	3.7	11
148	Lipotoxicity on the basis of metabolic syndrome and lipodystrophy in HIV-1-infected patients under antiretroviral treatment. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3371-8	3.3	14
147	Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. <i>AIDS Reviews</i> , 2010 , 12, 3-14	1.5	21
146	Pharmacogenetics of adverse effects due to antiretroviral drugs. <i>AIDS Reviews</i> , 2010 , 12, 15-30	1.5	29
145	Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). <i>Clinical Infectious Diseases</i> , 2009 , 49, 892-900	11.6	32
144	Bacterial meningitis in HIV-1-infected patients in the era of highly active antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009 , 51, 582-7	3.1	32
143	Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression. <i>HIV Clinical Trials</i> , 2009 , 10, 432-8		9

142	HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain. <i>Current HIV Research</i> , 2009 , 7, 597-600	1.3	25
141	The changing face of HIV/AIDS in treated patients. <i>Current HIV Research</i> , 2009 , 7, 365-77	1.3	25
140	HIV-1 infection and the PPAR δ -dependent control of adipose tissue physiology. <i>PPAR Research</i> , 2009 , 2009, 607902	4.3	12
139	Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 50, 390-6	3.1	13
138	Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 29-36	3.1	71
137	Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 189-96	5.1	5
136	PPAR γ Pro12Ala polymorphism in HIV-1-infected patients with HAART-related lipodystrophy. <i>Current HIV Research</i> , 2009 , 7, 533-40	1.3	12
135	Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 681-92	6.2	38
134	Impaired expression of mitochondrial and adipogenic genes in adipose tissue from a patient with acquired partial lipodystrophy (Barraquer-Simons syndrome): a case report. <i>Journal of Medical Case Reports</i> , 2008 , 2, 284	1.2	10
133	Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008 , 62, 34-43	2.9	40
132	First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 1348-58	5.1	24
131	The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 234-45	5.1	30
130	Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1083-92	11.6	29
129	Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPAR(γ):RXR heterodimers: comparison with other polyunsaturated fatty acids. <i>Journal of Leukocyte Biology</i> , 2008 , 84, 1172-82	6.5	94
128	Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults. <i>Aids</i> , 2008 , 22, 377-84	3.5	13
127	Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study. <i>AIDS Research and Human Retroviruses</i> , 2008 , 24, 931-4	1.6	4
126	Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008 , 49, 26-31	3.1	63
125	The IL-6 system in HIV-1-infection and in HAART-related fat redistribution syndromes. <i>Aids</i> , 2008 , 22, 893-6	3.5	18

124	Differential gene expression indicates that Buffalo hump is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy. <i>Aids</i> , 2008 , 22, 575-84	3.5	44
123	Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 206-9	5.1	7
122	Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort. <i>Open AIDS Journal</i> , 2008 , 2, 26-38	0.6	15
121	Análisis de minimización de costes de diferentes combinaciones de inhibidores de la transcriptasa inversa análogos de nucleósidos asociados a acontecimientos adversos en pacientes infectados por el VIH-1. <i>Pharmacoeconomics - Spanish Research Articles</i> , 2007 , 4, 25-36		0
120	Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 85-92	6.2	14
119	9-cis-Retinoic acid (9cRA), a retinoid X receptor (RXR) ligand, exerts immunosuppressive effects on dendritic cells by RXR-dependent activation: inhibition of peroxisome proliferator-activated receptor gamma blocks some of the 9cRA activities, and precludes them to mature phenotype <i>Journal of Cellular Biochemistry</i> , 2007 , 105, 1122-32	5.3	53
118	HIV-1-infected long-term non-progressors have milder mitochondrial impairment and lower mitochondrially-driven apoptosis in peripheral blood mononuclear cells than typical progressors. <i>Current HIV Research</i> , 2007 , 5, 467-73	1.3	24
117	Polymorphisms in the 3' untranslated region of the fractalkine (CX3CL1) gene and the risk of HIV-1 infection and disease progression. <i>Aids</i> , 2007 , 21, 891-3	3.5	2
116	Strategies in the treatment of HIV-1-associated adipose redistribution syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 1871-84	4	5
115	Bilateral Bell palsy and acute HIV type 1 infection: report of 2 cases and review. <i>Clinical Infectious Diseases</i> , 2007 , 44, e57-61	11.6	42
114	Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 690-7	5.1	52
113	Air-leak syndromes in hematopoietic stem cell transplant recipients with chronic GVHD: high-resolution CT findings. <i>Journal of Thoracic Imaging</i> , 2007 , 22, 335-40	5.6	35
112	Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients. <i>Aids</i> , 2007 , 21, 367-9	3.5	16
111	Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection: CCL2-2518GG is overrepresented in a cohort of Spanish HIV-1-infected subjects. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 44, 132-8	3.1	24
110	Mechanisms of antiretroviral-induced mitochondrial dysfunction in adipocytes and adipose tissue: in-vitro, animal and human adipose tissue studies. <i>Current Opinion in HIV and AIDS</i> , 2007 , 2, 261-7	4.2	6
109	Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. <i>Aids</i> , 2007 , 21, 169-78	3.5	65
108	A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. <i>AIDS Research and Human Retroviruses</i> , 2007 , 23, 1505-14	1.6	56
107	Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with ¹ H-MR spectroscopy. <i>Antiviral Therapy</i> , 2007 , 12, 195-203	1.6	6

106	Altered expression of nucleoside transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patients. <i>Antiviral Therapy</i> , 2007 , 12, 853-63	1.6	11
105	Altered Expression of Nucleoside Transporter Genes (SLC28 and SLC29) in Adipose Tissue from HIV-1 Infected Patients. <i>Antiviral Therapy</i> , 2007 , 12, 853-864	1.6	16
104	Liver Triglyceride Content in HIV-1-Infected Patients on Combination Antiretroviral Therapy Studied with 1H-MR Spectroscopy. <i>Antiviral Therapy</i> , 2007 , 12, 195-204	1.6	13
103	Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 42, 385-7	3.1	22
102	In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 3824-32	5.9	55
101	Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 321-9	1.6	41
100	Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. <i>Clinical Infectious Diseases</i> , 2006 , 43, 79-89	11.6	36
99	Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006 , 56, 153-60	2.9	86
98	Altered expression of master regulatory genes of adipogenesis in lipomas from patients bearing tRNA(Lys) point mutations in mitochondrial DNA. <i>Molecular Genetics and Metabolism</i> , 2006 , 89, 283-5	3.7	16
97	Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 years. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 17-22	3.1	21
96	Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. <i>Aids</i> , 2006 , 20, 2075-80	3.5	37
95	Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. <i>Aids</i> , 2006 , 20, 1407-14	3.5	58
94	Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 598-606	3.1	22
93	Absence of CXCR4 C-terminal polymorphisms in HIV-1-infected and uninfected Spaniards. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 42, 382-3	3.1	2
92	HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy. <i>Antiviral Therapy</i> , 2006 , 11, 729-40	1.6	59
91	HIV-1 Infection Alters Gene Expression in Adipose Tissue, Which Contributes to HIV-1/Haart-Associated Lipodystrophy. <i>Antiviral Therapy</i> , 2006 , 11, 729-740	1.6	90
90	Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. <i>Aids</i> , 2005 , 19, 1385-91	3.5	10
89	Inmunoterapia y vacunas terapéuticas en la infección por VIH. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2005 , 23, 84-94	0.9	2

88	Immunotherapy and therapeutic vaccines in HIV infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2005 , 23, 95-104	0.9	1
87	Antiagregantes plaquetarios y su influencia en la estancia hospitalaria y consumo de recursos sanitarios en pacientes ancianos con fractura de fémur. <i>Revista De Calidad Asistencial: Órgano De La Sociedad Española De Calidad Asistencial</i> , 2005 , 20, 251-255		
86	Disseminated cryptococcosis resembling millitary tuberculosis in an HIV-1-infected patient. <i>Lancet Infectious Diseases</i> , 2005 , 5, 189	25.5	3
85	Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. <i>Trends in Pharmacological Sciences</i> , 2005 , 26, 88-93	13.2	66
84	Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 317-23	3.1	24
83	Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. <i>Aids</i> , 2005 , 19, 569-75	3.5	62
82	Spanish HIV-1-infected long-term nonprogressors of more than 15 years have an increased frequency of the CX3CR1 249I variant allele. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 527-31	3.1	35
81	Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. <i>Journal of Medical Virology</i> , 2005 , 77, 23-8	19.7	20
80	Lack of association of SDF-1 30A variant allele with long-term nonprogressive HIV-1 infection is extended beyond 16 years. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 276-9	3.1	16
79	Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes. <i>Antiviral Therapy</i> , 2005 , 10, 515-26	1.6	7
78	Reverse Transcriptase Inhibitors Alter Uncoupling Protein-1 and Mitochondrial Biogenesis in Brown Adipocytes. <i>Antiviral Therapy</i> , 2005 , 10, 515-526	1.6	19
77	Simplification Therapy with Once-Daily Didanosine, Tenofovir and Efavirenz in HIV-1-Infected Adults with Viral Suppression Receiving a More Complex Antiretroviral Regimen: Final Results of the EFADITE Trial. <i>Antiviral Therapy</i> , 2005 , 10, 825-832	1.6	13
76	Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. <i>Clinical Infectious Diseases</i> , 2004 , 38, 565-71	11.6	102
75	Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. <i>Clinical Infectious Diseases</i> , 2004 , 38, 1017-23	11.6	69
74	Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study. <i>Clinical Infectious Diseases</i> , 2004 , 39, 1514-9	11.6	24
73	Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. <i>Aids</i> , 2004 , 18, 1475-8	3.5	35
72	Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less. <i>Aids</i> , 2004 , 18, 1727-9	3.5	10
71	Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004 , 37, 1276-81	3.1	10

70	Uncoupling protein 1 gene expression implicates brown adipocytes in highly active antiretroviral therapy-associated lipomatosis. <i>Aids</i> , 2004 , 18, 959-60	3.5	23
69	Could mitochondrial DNA quantitation be a surrogate marker for drug mitochondrial toxicity?. <i>AIDS Reviews</i> , 2004 , 6, 169-80	1.5	15
68	Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 4421-3	9.7	10
67	Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , 2003 , 349, 1036-46	59.2	268
66	Infectious pulmonary nodules in immunocompromised patients: usefulness of computed tomography in predicting their etiology. <i>Journal of Computer Assisted Tomography</i> , 2003 , 27, 461-8	2.2	68
65	Effect of protease inhibitors on apolipoprotein B levels and plasma lipid profile in HIV-1-infected patients on highly active antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 33, 114-6	3.1	4
64	Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. <i>Annals of Internal Medicine</i> , 2003 , 139, 81-9	8	33
63	Hepatitis C virus and human immunodeficiency virus coinfection in Spain. <i>Journal of Infection</i> , 2003 , 47, 117-24	18.9	28
62	Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2003 , 36, 1047-52	11.6	113
61	Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor. <i>Antiviral Therapy</i> , 2003 , 8, 223-31	1.6	13
60	Fat Distribution and Metabolic Abnormalities in HIV-Infected Patients on First Combination Antiretroviral Therapy Including Stavudine or Zidovudine: Role of Physical Activity as a Protective Factor. <i>Antiviral Therapy</i> , 2003 , 8, 223-231	1.6	23
59	Effects of Metformin Or Gemfibrozil on the Lipodystrophy of HIV-Infected Patients Receiving Protease Inhibitors. <i>Antiviral Therapy</i> , 2003 , 8, 403-410	1.6	21
58	Ultrastructural features of highly active antiretroviral therapy-associated partial lipodystrophy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002 , 441, 599-604	5.1	39
57	Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. <i>Clinical Infectious Diseases</i> , 2002 , 34, 838-46	11.6	152
56	Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. <i>Aids</i> , 2002 , 16, 209-18	3.5	213
55	Absence of mutations in exon 8 of the gene in combination antiretroviral therapy-associated partial lipodystrophy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 30, 457-8	3.1	5
54	Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. <i>American Journal of Medicine</i> , 2002 , 112, 19-25	2.4	61
53	Absence of Mutations in Exon 8 of the LMNA Gene in Combination Antiretroviral Therapy-Associated Partial Lipodystrophy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 30, 457-458	3.1	0

52	Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug. <i>Aids</i> , 2002 , 16, 1299-301	3.5	5
51	Epidemiological trends of HIV infection in Spain. <i>Aids</i> , 2002 , 16, 2496-2499	3.5	13
50	Efavirenz-induced leukocytoclastic vasculitis. <i>Archives of Internal Medicine</i> , 2002 , 162, 355-6		10
49	Epidemiological trends of HIV infection in Spain: preventative plans have to be oriented to new target populations (Spanish VACH Cohort). <i>Aids</i> , 2002 , 16, 2496-9	3.5	4
48	Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. <i>Aids</i> , 2001 , 15, 1701-6	3.5	49
47	Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 27, 229-36	3.1	113
46	Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 28, 14-8	3.1	27
45	Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy. <i>Journal of Infectious Diseases</i> , 2001 , 184, 1197-201	7	51
44	A randomized trial of the discontinuation of primary and secondary prophylaxis against <i>Pneumocystis carinii</i> pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. <i>New England Journal of Medicine</i> , 2001 , 344, 159-67	59.2	176
43	Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. <i>American Journal of Medicine</i> , 2001 , 110, 605-9	2.4	120
42	Management of complications associated with totally implantable ports in patients with AIDS. <i>AIDS Patient Care and STDs</i> , 2001 , 15, 7-13	5.8	14
41	Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor-Experienced Patients With HIV-Associated Lipodystrophy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 27, 229-236	3.1	55
40	Meningococemia 2001 , 473-502		
39	^{99m} Tc-HMPAO SPET: a method to study visual loss in cryptococcal meningitis. <i>Acta Neurologica Scandinavica</i> , 2000 , 102, 340-1	3.8	2
38	Semiinvasive pulmonary aspergillosis in chronic obstructive pulmonary disease: radiologic and pathologic findings in nine patients. <i>American Journal of Roentgenology</i> , 2000 , 174, 51-6	5.4	48
37	Lateral decubitus CT: a useful adjunct to standard inspiratory-expiratory CT for the detection of air-trapping. <i>American Journal of Roentgenology</i> , 2000 , 174, 528-30	5.4	12
36	Prospective study of new-onset seizures in patients with human immunodeficiency virus infection: etiologic and clinical aspects. <i>Archives of Neurology</i> , 1999 , 56, 609-12		54
35	Morbidity associated with long-term use of totally implantable ports in patients with AIDS. <i>Clinical Infectious Diseases</i> , 1999 , 29, 346-51	11.6	44

34	Acute Q fever in adult patients: report on 63 sporadic cases in an urban area. <i>Clinical Infectious Diseases</i> , 1999 , 29, 874-9	11.6	34
33	Lipodystrophy in HIV-1-infected patients. <i>Lancet, The</i> , 1999 , 354, 868	4.0	8
32	Beta 2-microglobulin and immunoglobulins are more useful markers of disease progression in HIV than neopterin and adenosine deaminase. <i>Annals of Clinical Biochemistry</i> , 1999 , 36 (Pt 5), 601-8	2.2	6
31	Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. <i>Aids</i> , 1999 , 13, 2261-7	3.5	171
30	Air trapping in primary Sjögren syndrome: correlation of expiratory CT with pulmonary function tests. <i>Journal of Computer Assisted Tomography</i> , 1999 , 23, 169-73	2.2	39
29	Meningococcal meningitis during penicillin therapy for meningococemia. <i>Clinical Infectious Diseases</i> , 1997 , 25, 1479	11.6	18
28	Group B streptococcal meningitis in adults: report of twelve cases and review. <i>Clinical Infectious Diseases</i> , 1997 , 25, 1180-7	11.6	98
27	Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy. <i>Lancet, The</i> , 1997 , 349, 1554-5	4.0	31
26	Successful liver transplantation using a polycystic donor liver. <i>Journal of Hepatology</i> , 1997 , 26, 1428	13.4	6
25	Bacterial meningitis and the painful eye. <i>Lancet, The</i> , 1996 , 347, 122-3	4.0	1
24	Invasive pneumococcal disease in HIV-1 infected patients. <i>Lancet, The</i> , 1996 , 347, 1414	4.0	1
23	Epstein-Barr virus infection associated with interstitial nephritis and chronic fatigue. <i>Scandinavian Journal of Infectious Diseases</i> , 1996 , 28, 185-7		9
22	Disseminated cytomegalovirus infection in an immunocompetent adult successfully treated with ganciclovir. <i>Scandinavian Journal of Infectious Diseases</i> , 1995 , 27, 523-5		8
21	Trimethoprim-sulfamethoxazole-induced renal tubular acidosis in a patient with AIDS. <i>Clinical Infectious Diseases</i> , 1995 , 20, 1435-7	11.6	8
20	Hemorrhagic stroke as a complication of bacterial meningitis in adults: report of three cases and review. <i>Clinical Infectious Diseases</i> , 1995 , 21, 1488-91	11.6	16
19	Aerosolized pentamidine prophylaxis of <i>Pneumocystis carinii</i> pneumonia in HIV-infected patients. <i>American Journal of Medicine</i> , 1995 , 98, 101-2	2.4	
18	Sore throat, antibiotics, and progression to meningococcal disease. <i>Lancet, The</i> , 1995 , 345, 460	4.0	2
17	<i>Moraxella catarrhalis</i> bacteraemia in an immunocompetent adult. <i>Scandinavian Journal of Infectious Diseases</i> , 1995 , 27, 95		7

16	Tuberculous pulmonary gangrene: report of a case and review. <i>Clinical Infectious Diseases</i> , 1994 , 18, 243-51.	1.6	8
15	Cellulitis after axillary lymph node dissection. <i>American Journal of Medicine</i> , 1994 , 97, 201-2	2.4	3
14	Brain biopsy for intracranial mass lesions in AIDS. <i>Lancet, The</i> , 1993 , 341, 242-243	4.0	3
13	Cerebrospinal fluid adenosine deaminase levels in a patient with cryptococcal meningitis. <i>Clinical Infectious Diseases</i> , 1992 , 15, 1061-2	11.6	10
12	Evans® syndrome triggered by recombinant hepatitis B vaccine. <i>Clinical Infectious Diseases</i> , 1992 , 15, 1051	11.6	20
11	Antibiotic prophylaxis and endocarditis. <i>Lancet, The</i> , 1992 , 339, 738	4.0	
10	Pneumococcal bacteraemia in immunocompetent adults. <i>Lancet, The</i> , 1991 , 337, 57	4.0	28
9	Bacterial meningitis with "normal" cerebrospinal fluid in adults: a report on five cases. <i>Scandinavian Journal of Infectious Diseases</i> , 1990 , 22, 115-6		16
8	Primary meningococcal conjunctivitis: report of 21 patients and review. <i>Clinical Infectious Diseases</i> , 1990 , 12, 838-47	11.6	68
7	Acute Bacterial Meningitis in the Elderly. <i>Archives of Internal Medicine</i> , 1990 , 150, 1546		5
6	Acute appendicitis complicating infectious mononucleosis: case report and review. <i>Clinical Infectious Diseases</i> , 1990 , 12, 297-302	11.6	23
5	Erythema nodosum and hepatitis C. <i>Lancet, The</i> , 1990 , 336, 1377	4.0	36
4	Liver involvement in acute Q fever. <i>Chest</i> , 1988 , 94, 895-6	5.3	8
3	Consumptive coagulopathy associated with aortic aneurysm. <i>American Journal of Medicine</i> , 1987 , 83, 189-90	2.4	4
2	Multiple Myeloma With Polyneuropathy and Coagulopathy. <i>Archives of Internal Medicine</i> , 1986 , 146, 2089		2
1	Cutaneous angiomas in POEMS syndrome. <i>Journal of the American Academy of Dermatology</i> , 1985 , 12, 961-4	4.5	35